1Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Molancer Therapeutics, 2007,6:1629-1640.
2Nahta R,Yuan LX, I)u Y, et al. Lapatinib induces apoptosis in trastuzumab- resistant breast cancer cells: effects on insulin-like growth factor Ⅰ signaling. Mol cancer ther, 2007,6:667-674.
3Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase Ⅰ safety, phannacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J clin oncol, 2005, 23: 5305- 5313.
4Howard A, Burris I,Herbert I,et al.Phase I ssfety pharmacokinetics and clinical activity study of lapatinib ( GW572016 ), a reversible'dual inhibitor of epidermal grontor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oneology, 2005, 23 : 5305-5313.
5Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist, 2004,9 (Suppl) : 10-15.
6Midgley RS, Kerr DJ, Flaherty KT, et al. A phase Ⅰ and phannacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan, Ann Oncol, 2007,18:2025-2029.
7Agulnik M, Cohen EW, Cohen RB, et al. Phase Ⅱ study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. Journal of clinical oncology, 2007,25 : 3978-3984.
8Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby after first- trimester maternal exposure to lapatinib, Clin Breast Cancer, 2006, 7: 339- 341.
